Provided by Tiger Trade Technology Pte. Ltd.

Fate Therapeutics

1.23
+0.01000.82%
Volume:1.22M
Turnover:1.52M
Market Cap:143.00M
PE:-1.07
High:1.31
Open:1.20
Low:1.20
Close:1.22
52wk High:1.94
52wk Low:0.6611
Shares:116.26M
Float Shares:100.80M
Volume Ratio:0.64
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1500
EPS(LYR):-1.1500
ROE:-51.84%
ROA:-24.12%
PB:0.69
PE(LYR):-1.07

Loading ...

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

GlobeNewswire
·
Nov 25, 2025

Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts

TIPRANKS
·
Nov 18, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

TIPRANKS
·
Nov 17, 2025

Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks

TIPRANKS
·
Nov 16, 2025

Fate Therapeutics (FATE) Receives a Hold from Bank of America Securities

TIPRANKS
·
Nov 16, 2025

Analysts Have Conflicting Sentiments on These Healthcare Companies: Indaptus Therapeutics (INDP) and Fate Therapeutics (FATE)

TIPRANKS
·
Nov 14, 2025

Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment

TIPRANKS
·
Nov 13, 2025

Fate Therapeutics Q3 EPS $(0.27) Beats $(0.29) Estimate, Sales $1.741M Beat $1.535M Estimate

Benzinga
·
Nov 13, 2025

Fate Therapeutics reports Q3 EPS (27c), consensus (28c)

TIPRANKS
·
Nov 13, 2025

Fate Therapeutics reports third quarter 2025 revenue of $1.7 million

Reuters
·
Nov 13, 2025

Fate Therapeutics Q3 Net Income USD -32.25 Million

THOMSON REUTERS
·
Nov 13, 2025

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

GlobeNewswire
·
Nov 13, 2025

Fate Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Nov 05, 2025

Fate Therapeutics Shares Rise After HC Wainwright Upgrade

MT Newswires Live
·
Nov 01, 2025

HC Wainwright Upgrades Fate Therapeutics to Buy From Neutral, $5 Price Target

MT Newswires Live
·
Oct 31, 2025

Fate Therapeutics Raised to Buy From Neutral by HC Wainwright & Co.

Dow Jones
·
Oct 31, 2025

Fate Therapeutics Inc : H.c. Wainwright Raises to Buy From Neutral

THOMSON REUTERS
·
Oct 31, 2025

Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7

TIPRANKS
·
Oct 27, 2025

Fate Therapeutics Raised to Outperform From Neutral by Wedbush

Dow Jones
·
Oct 27, 2025